In what year was Pertuzumab launched in China?

Pertuzumab (Pertuzumab) can be administered intravenously in combination with trastuzumab and docetaxel. It was approved by the National Medical Products Administration in 2018 and was marketed in China under the trade name Padget. It was subsequently entered into the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Bureau, but only for HER2-positive locally advanced patients. , neoadjuvant treatment for patients with inflammatory or early-stage breast cancer, and adjuvant treatment for patients with HER2-positive early breast cancer with a high risk of recurrence, and medical insurance payment will not exceed 12 months.The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates).